seloken zoc forðatafla 190 mg
recordati ireland limited* - metoprololum súkkínat - forðatafla - 190 mg
seloken stungulyf, lausn 1 mg/ml
recordati ireland limited* - metoprololum tartrat - stungulyf, lausn - 1 mg/ml
bloxazoc forðatafla 25 mg
krka d.d. novo mesto - metoprololum súkkínat - forðatafla - 25 mg
nematel vet. (twinhip vet.) pasta til inntöku 439 mg/g
le vet beheer b.v. - pyrantelum embónat - pasta til inntöku - 439 mg/g
bloxazoc forðatafla 200 mg
krka d.d. novo mesto - metoprololum súkkínat - forðatafla - 200 mg
bloxazoc forðatafla 50 mg
krka d.d. novo mesto - metoprololum súkkínat - forðatafla - 50 mg
hemangiol
pierre fabre medicament - própranólól hýdróklóríð - hemangioma - betablokkar - hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy: , life- or function-threatening haemangioma,, ulcerated haemangioma with pain and/or lack of response to simple wound care measures,, haemangioma with a risk of permanent scars or disfigurement. , it is to be initiated in infants aged 5 weeks to 5 months.
yescarta
kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - Æxlishemjandi lyf - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.
tecartus
kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - eitilfrumukrabbamein, mantle-cell - Æxlishemjandi lyf - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).